Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Recommendation of “Hold” from Analysts

Moderna, Inc. (NASDAQ:MRNA) has received a consensus recommendation of “Hold” from the twenty research firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $94.65.

A number of equities research analysts recently weighed in on MRNA shares. Deutsche Bank Aktiengesellschaft raised Moderna from a “sell” rating to a “hold” rating and decreased their target price for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. UBS Group cut their target price on Moderna from $140.00 to $108.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. The Goldman Sachs Group decreased their price target on shares of Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research note on Monday, September 16th. Royal Bank of Canada restated a “sector perform” rating and issued a $75.00 price objective on shares of Moderna in a research note on Thursday, September 19th. Finally, TD Cowen decreased their target price on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th.

Moderna Stock Down 0.9 %

MRNA opened at $54.72 on Thursday. The business has a 50 day moving average of $66.34 and a 200-day moving average of $102.02. The stock has a market capitalization of $20.97 billion, a price-to-earnings ratio of -3.49 and a beta of 1.66. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. Moderna has a 1-year low of $52.26 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business’s quarterly revenue was down 29.9% on a year-over-year basis. During the same period last year, the business posted ($3.62) EPS. As a group, sell-side analysts anticipate that Moderna will post -9.88 earnings per share for the current year.

Insider Activity

In related news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Moderna news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO James M. Mock sold 715 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,184 shares of company stock worth $238,531. 15.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Moderna

Institutional investors and hedge funds have recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC bought a new stake in Moderna during the 2nd quarter worth about $26,000. Cedar Wealth Management LLC raised its stake in shares of Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after buying an additional 90 shares during the last quarter. Westside Investment Management Inc. acquired a new position in Moderna in the first quarter valued at approximately $32,000. Family Firm Inc. bought a new position in Moderna in the second quarter valued at approximately $33,000. Finally, Bank & Trust Co acquired a new stake in Moderna during the 2nd quarter worth $36,000. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.